Glaukos Corporation (NYSE:GKOS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Key Points

• Glaukos Corporation has received an average recommendation of "Moderate Buy" from fourteen research firms, with ten analysts issuing buy ratings and one a strong buy rating.
• The average 1-year price target for Glaukos among analysts is $123.58, with several firms setting targets as high as $134.00.
• Glaukos reported a quarterly EPS of ($0.24), exceeding expectations, and its revenue increased by 29.7% compared to the same quarter last year.

Glaukos Corporation (NYSE:GKOS - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the fourteen research firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, ten have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $123.5833.

Several research firms have recently weighed in on GKOS. William Blair raised shares of Glaukos to a "strong-buy" rating in a research note on Thursday, July 31st. Mizuho set a $130.00 price target on shares of Glaukos in a research note on Thursday, July 31st. BTIG Research reaffirmed a "buy" rating and set a $118.00 price target on shares of Glaukos in a research note on Wednesday, September 10th. UBS Group boosted their price objective on shares of Glaukos from $125.00 to $134.00 and gave the stock a "buy" rating in a research note on Thursday, July 31st. Finally, Zacks Research downgraded shares of Glaukos from a "strong-buy" rating to a "hold" rating in a research note on Friday, August 15th.

Hedge Funds Weigh In On Glaukos

A number of large investors have recently bought and sold shares of the business. Wellington Management Group LLP raised its stake in Glaukos by 6.1% in the first quarter. Wellington Management Group LLP now owns 2,290,790 shares of the medical instruments supplier's stock worth $225,460,000 after buying an additional 131,251 shares in the last quarter. State Street Corp raised its stake in Glaukos by 5.3% in the second quarter. State Street Corp now owns 2,090,365 shares of the medical instruments supplier's stock worth $215,914,000 after buying an additional 105,972 shares in the last quarter. Ameriprise Financial Inc. raised its stake in Glaukos by 3.5% in the second quarter. Ameriprise Financial Inc. now owns 1,999,252 shares of the medical instruments supplier's stock worth $206,503,000 after buying an additional 68,497 shares in the last quarter. Primecap Management Co. CA raised its stake in Glaukos by 50.0% in the second quarter. Primecap Management Co. CA now owns 1,827,998 shares of the medical instruments supplier's stock worth $188,814,000 after buying an additional 609,523 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in Glaukos by 9.5% in the second quarter. Geode Capital Management LLC now owns 1,330,593 shares of the medical instruments supplier's stock worth $137,454,000 after purchasing an additional 115,529 shares during the last quarter. Institutional investors own 99.04% of the company's stock.

Glaukos Stock Down 1.6%

Shares of NYSE GKOS opened at $81.45 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.51 and a quick ratio of 4.69. The company has a market cap of $4.67 billion, a P/E ratio of -49.36 and a beta of 0.77. Glaukos has a 1 year low of $77.10 and a 1 year high of $163.71. The firm has a 50-day simple moving average of $90.05 and a two-hundred day simple moving average of $94.11.

Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.02. Glaukos had a negative net margin of 21.43% and a negative return on equity of 8.59%. The business had revenue of $124.12 million during the quarter, compared to the consensus estimate of $115.49 million. During the same quarter last year, the firm earned ($0.52) earnings per share. The firm's quarterly revenue was up 29.7% compared to the same quarter last year. Glaukos has set its FY 2025 guidance at EPS. Research analysts anticipate that Glaukos will post -1.08 earnings per share for the current year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.